temozolomide;

Daisuke Sato1, Hirokazu Takami2, Shunsaku Takayanagi1

  • 1Department of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.

BMC neurology
|June 9, 2023
PubMed
概括

本案例报告详细介绍了在治疗脑干结质瘤时出现的其他催化性免疫缺陷相关的淋巴增殖障碍 (OIIA-LPD) 的第一例. 停止使用temozolomide导致缓解,突出其在治疗这种罕见并发症中的作用.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K